| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8158616 | ELI LILLY AND CO | Azetidine and cyclobutane derivatives as JAK inhibitors |
Jun, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8420629 | ELI LILLY AND CO | Azetidine and cyclobutane derivatives as JAK inhibitors |
Mar, 2029
(5 years from now) | |
| US9737469 | ELI LILLY AND CO | Methods for treating hair loss disorders |
Nov, 2031
(8 years from now) | |
| US9089574 | ELI LILLY AND CO | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
Nov, 2032
(9 years from now) | |
| US11045474 | ELI LILLY AND CO | Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections |
Nov, 2032
(9 years from now) | |
Olumiant is owned by Eli Lilly And Co.
Olumiant contains Baricitinib.
Olumiant has a total of 5 drug patents out of which 0 drug patents have expired.
Olumiant was authorised for market use on 31 May, 2018.
Olumiant is available in tablet;oral dosage forms.
Olumiant can be used as treatment of adult patients with severe alopecia areata, treatment of rheumatoid arthritis, treatment of coronavirus disease 2019 (covid-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo).
Drug patent challenges can be filed against Olumiant from 2022-05-31.
The generics of Olumiant are possible to be released after 30 November, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 31, 2023 |
| New Indication (I) | May 10, 2025 |
Drugs and Companies using BARICITINIB ingredient
NCE-1 date: 2022-05-31
Market Authorisation Date: 31 May, 2018
Treatment: Treatment of rheumatoid arthritis; Treatment of adult patients with severe alopecia areata; Treatment of coronavirus disease 2019 (covid-19) in hospitalized adults requiring supplemental oxygen, non-i...
Dosage: TABLET;ORAL
OLUMIANT family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic